Wiley led Jazz Pharma’s sleep medicines unit, including narcolepsy blockbuster Xyrem.
Neuroscience-focused BioXcel Therapeutics has appointed Matt Wiley as SVP and chief commercial officer (CCO), the biotech said Wednesday.
He brings over 25 years of commercial and industry expertise across multiple product launches, including neuroscience products.
Formerly CCO at Vyne Therapeutics, a dermatology drugmaker, Wiley’s career highlights include a stint as VP of marketing at Jazz Pharmaceuticals, where he led the sleep medicines unit.
While there, he directed the go-to-market strategy and marketing for Jazz’s narcolepsy med Sunosi upon its 2019 launch (it’s subsequently been approved for use with sleep apnea, too), and developed the growth strategy for older narcolepsy blockbuster Xyrem. He also served as VP of marketing at Azur Pharma, supporting the startup’s US operations and eventual acquisition by Jazz.
BioXcel is preparing for its first potential approval and commercial launch, BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders. The drug is slated for an FDA decision by April 5th.
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
There are a lot of questions and concerns about the Omicron variant. Dr. Monica Gandhi unpacks the nuances of Omicron and shares why she’s optimistic about where we are in the pandemic.
Caregivers are physically, financially and emotionally drained and don’t feel equipped or qualified to provide optimal care. How can pharma better support them?
Kimberly Jones, President & CEO of Butler/Till, talks with Marc Iskowitz about how her company is thriving, despite an incredibly tight job market and the ever-evolving marketing ecosystem.
MM+M’s GM Steve Madden sat down with Louis Naimoli, director of programmatic for Haylo, a subsidiary of Haymarket Medical Network, to discuss omnichannel marketing, its prevalence in the pharma industry, and more.
Create your free account or log in to continue reading this premium content.